Vioxx was easier on the stomach than aspirin, but it cost more.
It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.
The FDA safety officer in charge of the report, David Graham, concluded that Vioxx posed much greater cardiovascular risk than the other major drug in its class, Celebrex.
The numbers were small, in part because people with heart disease had been screened out of the trial, but the trend had been worrisome and the latest data were striking: After 18 months on the drug, the Vioxx group was clearly having more heart problems than the placebo group and the rate of difference was accelerating.
"When there are other alternatives, why risk trying to use the drug that might have elevated risk?